Timo Vesikari | Charles Explorer

Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2-or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months

2021 | Publikace bez příslušnosti k fakultě